Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

98.56 +0.37 (+0.38%)
Streaming Delayed Price Updated: 10:15 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Analyst Ratings for Axsome Therapeutics
Via Benzinga
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Today's market loser could be tomorrow's market winner. 
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
3 Explosive Stocks to Buy Right Now
These stocks are poised to pop in the not-too-distant future. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Fantastic Growth Stocks to Buy in August
These stocks could be poised to soar. 
Via The Motley Fool
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
There's lots of upside potential for these drugmakers. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.